Concepedia

Author

Minish Jain

Ruby Hall ClinicORCID

Also Known As

M Jain, M. Jain, M. M. Jain, Maneesh R. Jain, Maneesh Jain, Maneesh R Jain, Maneesh Rajiv Jain, Minish Jain, Minish M. Jain, Minish Mahendra Jain

114

Publications

1.4K

Citations

16

H-Index

53

Concepts

All Affiliations

Ruby Hall ClinicHCG NCHRI Cancer CentreTata Memorial HospitalKidwai Memorial Institute of OncologyAdvaxis (United States)
MJ

About

Minish Jain is an author at Ruby Hall Clinic specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

617

2

Health Sciences

5

5

99

3

Public Health

2

2

53

4

Biochemistry

1

1

59

5

Head And Neck Surgery

1

1

26

Minish Jain

×

19

Publications

1.1K

Citations

14

H-Index

YearCitations

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

Giuseppe Giaccone, Lyudmila Bazhenova, John Nemunaitis,

European Journal of Cancer

2015

266

A Randomized Phase 2 Study of ADXS11-001 Listeria monocy'togenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer

Partha Basu, Ajay Mehta, Minish Jain,

International Journal of Gynecological Cancer

2018

171

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park,

Annals of Oncology

2015

131

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study

Kevin J. Harrington, Stéphane Temam, Hisham Mehanna,

Journal of Clinical Oncology

2015

102

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

William J. Gradishar, Virginia Kaklamani, Tarini Prasad Sahoo,

European Journal of Cancer

2012

84

The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer:

Andrew J.S. Coats, Venkatesan Srinivasan, J Surendran,

Journal of Cachexia Sarcopenia and Muscle

2011

59

Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study

Minish Jain, Smita Uday Gupte, Shekhar G. Patil,

Breast Cancer Research and Treatment

2016

55

Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care

P. P. Bapsy, Bandana Sharan, Chaitanya Kumar,

Cytotherapy

2014

43

A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).

William J. Gradishar, Virginia Kaklamani, T. Prasad Sahoo,

Cancer Research

2009

37

ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer.

Partha Basu, Ajay Mehta, Minish Jain,

Journal of Clinical Oncology

2014

32

Page 1